Dynamics of targeted cancer therapy

Trends in Molecular Medicine

Volumn 18, Issue 6, 2012, Pages 311-316

  Bozic, Ivana ^a,b   Allen, Benjamin ^a   Nowak, Martin A ^a,b  

^a HARVARD UNIVERSITY   (United States)

^b HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEFITINIB;

CANCER GROWTH; CANCER RESISTANCE; CANCER THERAPY; CELL DEATH; CELL DIVISION; DRUG TARGETING; GEOMETRY; HUMAN; MATHEMATICAL MODEL; MOLECULAR DYNAMICS; REVIEW;

DRUG RESISTANCE, NEOPLASM; HUMANS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 84861904282     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2012.04.006     Document Type: Review

References (61)

1. Sawyers C. Targeted cancer therapy. Nature 2004, 432:294-297.
2. Imai K., Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat. Rev. Cancer 2006, 6:714-727.
3. Gambacorti-Passerini C. Part I: milestones in personalised medicine - imatinib. Lancet Oncol. 2008, 9:600.
4. Gerber D.E., Minna J.D. ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time. Cancer Cell 2010, 18:548-551.
5. Druker B.J., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 2006, 355:2408-2417.
6. Gambacorti-Passerini C., et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J. Natl. Cancer Inst. 2011, 103:553-561.
7. Maemondo M., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 2010, 362:2380-2388.
8. Pao W., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005, 2:e73.
9. Antonescu C.R., et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin. Cancer Res. 2005, 11:4182-4190.
10. O'Hare T., et al. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007, 110:2242-2249.
11. Ercan D., et al. Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene 2010, 29:2346-2356.
12. Turke A.B., et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010, 17:77-88.
13. Nazarian R., et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010, 468:973-977.
14. Nowak M.A., et al. Antigenic diversity thresholds and the development of AIDS. Science 1991, 254:963-969.
15. Nowak M.A., May R.M. Mathematical biology of HIV infections: antigenic variation and diversity threshold. Math. Biosci. 1991, 106:1-21.
16. Ho D.D., et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123-126.
17. Wei X., et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995, 373:117-122.
18. Nowak M.A., May R.M. Virus Dynamics: Mathematical Principles of Immunology and Virology 2000, Oxford University Press.
19. Coffin J.M. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995, 267:483-489.
20. Bonhoeffer S., et al. Virus dynamics and drug therapy. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:6971-6976.
21. Bonhoeffer S., Nowak M.A. Pre-existence and emergence of drug resistance in HIV-1 infection. Proc. R. Soc. Lond. B: Biol. Sci. 1997, 264:631-637.
22. Nordling C.O. A new theory on the cancer-inducing mechanism. Br. J. Cancer 1953, 7:68-72.
23. Armitage P., Doll R. The age distribution of cancer and a multi-stage theory of carcinogenesis. Br. J. Cancer 1954, 8:1-12.
24. Armitage P., Doll R. A two-stage theory of carcinogenesis in relation to the age distribution of human cancer. Br. J. Cancer 1957, 11:161-169.
25. Moolgavkar S.H., Knudson A.G. Mutation and cancer: a model for human carcinogenesis. J. Natl. Cancer Inst. 1981, 66:1037-1052.
26. Moolgavkar S.H., Luebeck E.G. Multistage carcinogenesis and the incidence of human cancer. Genes Chrom. Cancer 2003, 38:302-306.
27. Beerenwinkel N., et al. Genetic progression and the waiting time to cancer. PLoS Comput. Biol. 2007, 3:e225.
28. Dingli D., et al. Stochastic dynamics of hematopoietic tumor stem cells. Cell Cycle 2007, 6:461-466.
29. Gatenby R.A., Gillies R.J. A microenvironmental model of carcinogenesis. Nat. Rev. Cancer 2008, 8:56-61.
30. Meza R., et al. Age-specific incidence of cancer: phases, transitions, and biological implications. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:16284-16289.
31. Bozic I., et al. Accumulation of driver and passenger mutations during tumor progression. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:18545-18550.
32. Yachida S., et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010, 467:1114-1117.
33. Goldie J.H., Coldman A.J. Drug Resistance in Cancer: Mechanisms and Models 1998, Cambridge University Press.
34. Michor F., et al. Dynamics of chronic myeloid leukaemia. Nature 2005, 435:1267-1270.
35. Komarova N.L., Wodarz D. Drug resistance in cancer: principles of emergence and prevention. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:9714-9719.
36. Iwasa Y., et al. Evolution of resistance during clonal expansion. Genetics 2006, 172:2557-2566.
37. Attolini C.S-O., Michor F. Evolutionary theory of cancer. Ann. N.Y. Acad. Sci. 2009, 1168:23-51.
38. Goldie J.H., Coldman A.J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat. Rep. 1979, 63:1727-1733.
39. Goldie J.H., et al. Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat. Rep. 1982, 66:439-449.
40. Coldman A.J., Goldie J.H. A model for the resistance of tumor cells to cancer chemotherapeutic agents. Math. Biosci. 1983, 65:291-307.
41. Goldie J.H., Coldman A.J. Quantitative model for multiple levels of drug resistance in clinical tumors. Cancer Treat. Rep. 1983, 67:923-931.
42. Coldman A.J., et al. The effect of cellular differentiation on the development of permanent drug resistance. Math. Biosci. 1985, 74:177-198.
43. Coldman A.J., Goldie J.H. A stochastic model for the origin and treatment of tumors containing drug-resistant cells. Bull. Math. Biol. 1986, 48:279-292.
44. Goldie J.H., Coldman A.J. Application of theoretical models to chemotherapy protocol design. Cancer Treat. Rep. 1986, 70:127-131.
45. Haeno H., et al. The evolution of two mutations during clonal expansion. Genetics 2007, 177:2209-2221.
46. Durrett R., Moseley S. Evolution of resistance and progression to disease during clonal expansion of cancer. Theoret. Pop. Biol. 2010, 77:42-48.
47. Iwasa Y., et al. Evolutionary dynamics of escape from biomedical intervention. Proc. R. Soc. Lond. B: Biol. Sci. 2003, 270:2573-2578.
48. Iwasa Y., et al. Evolutionary dynamics of invasion and escape. J. Theoret. Biol. 2004, 226:205-214.
49. Michor F., et al. Evolution of resistance to cancer therapy. Curr. Pharm. Des. 2006, 12:261-271.
50. Komarova N. Stochastic modeling of drug resistance in cancer. J. Theoret. Biol. 2006, 239:351-366.
51. Hart D., et al. The growth law of primary breast cancer as inferred from mammography screening trials data. Br. J. Cancer 1998, 78:382-387.
52. Spratt J.A., et al. Decelerating growth and human breast cancer. Cancer 1993, 71:2013-2019.
53. Vaupel P., et al. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 1989, 49:6449-6465.
54. Jones S., et al. Comparative lesion sequencing provides insights into tumor evolution. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:4283-4288.
55. Jiang Y., et al. A multiscale model for avascular tumor growth. Biophys. J. 2005, 89:3884-3894.
56. Yun J., et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 2009, 325:1555-1559.
57. Athreya K.B., Ney P. Branching Processes 2004, Dover Pubns.
58. Azad N.S., et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J. Clin. Oncol. 2008, 26:3709-3714.
59. Komarova N.L., et al. Combination of two but not three current targeted drugs can improve therapy of chronic myeloid leukemia. PLoS ONE 2009, 4:e4423.
60. Sosman J.A., et al. Opportunities and obstacles to combination targeted therapy in renal cell cancer. Clin. Cancer Res. 2007, 13:764s-769s.
61. Nimeiri H.S., et al. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II consortia. Gynecol. Oncol. 2008, 110:49-55.